Some good news for emerging-market ambitions: China is backpedaling on price caps. After shortages prompted the government to ease up on certain price controls earlier this year, officials are now preparing to lift the price controls as early as Jan. 1.
Actavis has a lot to do as it works to bring new acquisition Allergan into the fold. And finding ways to grow the California company's products in China is high on the list.
The FDA is extending its tentacles deeper into China, which exported medical devices worth $3.5 billion to the U.S. in 2012, according to the U.S. Department of Commerce.
Minnesota-based device giant St. Jude Medical is beating the bushes in Malaysia, possibly looking to expand its production and services operations there, Malaysia's New Straits Times reported.
Neopharma, based in the United Arab Emirates, will build a plant in a new industrial city being developed in the south of the country. B.R. Shetty, who controls both Neopharma and New Medical Center Group of Companies, has pledged to spend 1 billion Saudi riyals ($266.5 million) to build both a drug manufacturing facility and a hospital in Jarzan City.
When Merck's Indian JV, Hilleman Laboratories, teamed up in June with Swedish biotech Gotovax AB, the plan was to get an affordable cholera vaccine to the developing world. Just a few months out, it's inked a pact to make that happen faster.
Bribery and pricing investigations aren't scaring Johnson & Johnson away from China. CEO Alex Gorsky tells The Wall Street Journal that his company is expanding full speed ahead in the fast-growing emerging market--and is actively looking at deals there to boost pharma sales.
Building political tensions between Russia and the West are making it increasingly difficult for drugmakers in the region, prompting Germany's Fresenius to dump a partnership there. The announcement comes as other drug companies have reported their businesses are under pressure in the area.
Roche is planning to make a major splash in China, looking to spend 450 million Swiss Francs ($466.2 million) to build a diagnostics operation in Suzhou.
Bristol-Myers Squibb is taking Gilead's lead when it comes to developing-world access for its hepatitis C drug, offering up a tiered pricing strategy and licensing agreements with generics makers. But according to some critics, that's not enough.